company background image
HLS

HLS Therapeutics TSX:HLS Stock Report

Last Price

CA$13.48

Market Cap

CA$437.7m

7D

7.8%

1Y

-20.2%

Updated

24 May, 2022

Data

Company Financials +
HLS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends1/6

HLS Stock Overview

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally.

HLS Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HLS Therapeutics
Historical stock prices
Current Share PriceCA$13.48
52 Week HighCA$20.52
52 Week LowCA$11.98
Beta0.76
1 Month Change-7.29%
3 Month Change-4.40%
1 Year Change-20.19%
3 Year Change-15.86%
5 Year Changen/a
Change since IPO16.31%

Recent News & Updates

May 25
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of September, with...

May 10
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of September, with...

Shareholder Returns

HLSCA HealthcareCA Market
7D7.8%-1.9%-0.7%
1Y-20.2%-25.9%5.2%

Return vs Industry: HLS exceeded the Canadian Healthcare industry which returned -25.2% over the past year.

Return vs Market: HLS underperformed the Canadian Market which returned 4.8% over the past year.

Price Volatility

Is HLS's price volatile compared to industry and market?
HLS volatility
HLS Average Weekly Movement5.4%
Healthcare Industry Average Movement9.0%
Market Average Movement9.8%
10% most volatile stocks in CA Market16.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: HLS is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: HLS's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201892Gilbert Godinhttps://www.hlstherapeutics.com

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests.

HLS Therapeutics Fundamentals Summary

How do HLS Therapeutics's earnings and revenue compare to its market cap?
HLS fundamental statistics
Market CapUS$340.37m
Earnings (TTM)-US$11.98m
Revenue (TTM)US$60.25m

5.6x

P/S Ratio

-28.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HLS income statement (TTM)
RevenueUS$60.25m
Cost of RevenueUS$9.77m
Gross ProfitUS$50.48m
Other ExpensesUS$62.46m
Earnings-US$11.98m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.37
Gross Margin83.78%
Net Profit Margin-19.88%
Debt/Equity Ratio58.7%

How did HLS perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

-43%

Payout Ratio

Does HLS pay a reliable dividends?

See HLS dividend history and benchmarks
When do you need to buy HLS by to receive an upcoming dividend?
HLS Therapeutics dividend dates
Ex Dividend DateJul 28 2022
Dividend Pay DateSep 15 2022
Days until Ex dividend63 days
Days until Dividend pay date112 days

Does HLS pay a reliable dividends?

See HLS dividend history and benchmarks

Valuation

Is HLS Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: HLS (CA$13.48) is trading below our estimate of fair value (CA$104.02)

Significantly Below Fair Value: HLS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HLS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Canadian Healthcare industry average.

PE vs Market: HLS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HLS is overvalued based on its Price-To-Book Ratio (2.1x) compared to the CA Healthcare industry average (2x).


Future Growth

How is HLS Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


60.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: HLS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HLS's is expected to become profitable in the next 3 years.

Revenue vs Market: HLS's revenue (35.1% per year) is forecast to grow faster than the Canadian market (6.4% per year).

High Growth Revenue: HLS's revenue (35.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HLS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has HLS Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HLS is currently unprofitable.

Growing Profit Margin: HLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HLS is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare HLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-38.1%).


Return on Equity

High ROE: HLS has a negative Return on Equity (-7.53%), as it is currently unprofitable.


Financial Health

How is HLS Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: HLS's short term assets ($43.9M) exceed its short term liabilities ($26.4M).

Long Term Liabilities: HLS's short term assets ($43.9M) do not cover its long term liabilities ($85.1M).


Debt to Equity History and Analysis

Debt Level: HLS's net debt to equity ratio (44.4%) is considered high.

Reducing Debt: HLS's debt to equity ratio has reduced from 81.2% to 58.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable HLS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: HLS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 35.2% per year.


Dividend

What is HLS Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.47%

Current Dividend Yield

Upcoming Dividend Payment

TodayMay 25 2022Ex Dividend DateJul 28 2022Dividend Pay DateSep 15 202249 days from Ex DividendBuy in the next 63 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: HLS's dividend (1.47%) isn’t notable compared to the bottom 25% of dividend payers in the Canadian market (1.9%).

High Dividend: HLS's dividend (1.47%) is low compared to the top 25% of dividend payers in the Canadian market (4.91%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, HLS has been paying a dividend for less than 10 years.

Growing Dividend: HLS's dividend payments have increased, but the company has only paid a dividend for 4 years.


Earnings Payout to Shareholders

Earnings Coverage: HLS is paying a dividend but the company is unprofitable.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (42.2%), HLS's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Gilbert Godin (62 yo)

1.58yrs

Tenure

US$1,351,402

Compensation

Mr. Gilbert Godin Co-founded HLS Therapeutics Inc. in 2014 and has been its Chief Executive Officer and Director since October 1, 2020. Mr. Godin served as President and Chief Operating Officer at HLS Ther...


CEO Compensation Analysis

Compensation vs Market: Gilbert's total compensation ($USD1.35M) is above average for companies of similar size in the Canadian market ($USD982.51K).

Compensation vs Earnings: Gilbert's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: HLS's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: HLS's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HLS insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

HLS Therapeutics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: HLS Therapeutics Inc.
  • Ticker: HLS
  • Exchange: TSX
  • Founded: 2018
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: CA$437.673m
  • Shares outstanding: 32.47m
  • Website: https://www.hlstherapeutics.com

Number of Employees


Location

  • HLS Therapeutics Inc.
  • 10 Carlson Court
  • Suite 701
  • Etobicoke
  • Ontario
  • M9W 6L2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.